Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Emory University
Study ID
NCT06495138
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Accepted

Interventions

  • StableEyes — DEVICE
    Gaze stabilization exercises using the StableEyes device for the incremental vestibular-ocular reflex adaptation approach. The StableEyes device consists of a lightweight head unit with a 9-dimension inertial measurement unit and electrostatic micro-mirror that dynamically controls the 2-dimensional position of a 1-milliwatt red laser projected on a wall 1 meter in front of the subject. StableEyes is controlled via a lightweight control unit with a touchscreen interface tethered by cable to the head unit.

Study Details

The study aims to study the effects of a novel treatment for vestibular symptoms in people with multiple sclerosis. The main objective is to determine whether daily personalized gaze stabilization training is more beneficial than intermittent gaze stability training in people with multiple sclerosis.

Key Dates

Start date
Apr 21, 2025
Status verified
Jul 2025
Primary completion
Sep 30, 2026
Completion
Mar 31, 2027

Study Design

Enrollment
138 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Daily Incremental Vestibulo-ocular Reflex Adaptation (D-IVA-GSE)
    The dosages of the D-IVA-GSE and I-IVA-GSE are based on the FITT principle of exercise prescription (frequency, intensity, time, and type). The D-IVA-GSE group will perform two, 15- minute GSE sessions (30-minutes total per day), seven days per week.
  • Experimental: Intermittent incremental vestibulo-ocular Reflex Adaptation (I-IVA-GSE)
    The I-IVA-GSE group will perform two, 15-minute IVA-GSE sessions (30 minutes total), three days per week, with at least one day between each exercise day.
  • No Intervention: Helathy Control
    The healthy control group will complete the same baseline assessments as the subjects in the Multiple Sclerosis (MS) group to serve as normative reference data.

Primary Outcome Measure

Composite VOR gain (cVOR gain) [ Time Frame: Weeks 0,1,2,3,4,5,6, 7, and 18 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Emory UniveristyAtlantaGeorgia30329-

Find similar trials in Atlanta, GA

By condition
Multiple sclerosis
By specialty
NeurologyBrain disordersAutoimmune disease
By research site
Emory Univeristy· Atlanta, GA

Related Studies